CarThera closes €9M ($10.3M) Series B funding round
LogosFonds

€9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study […]

Read more »
CarThera closes €9M ($10.3M) Series B funding round
  • unnamed-2
    unnamed-3

     
  • News CarThera

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.

  • Category Archives: Uncategorized

    LogosFonds

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners,…

    Read more »
    ASCO2018

    Preliminary data from the first clinical trial of the company’s…

    Read more »
    logoBIO2018Small

    CarThera will participate to the BIO International Convention in Boston…

    Read more »
    ASCO

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of…

    Read more »
    bpifrance-logo

    October 12, 2016 – CarThera has received a grant of…

    Read more »
    Science

    SonoCloud® uses ultrasound to achieve permeability of blood vessels in…

    Read more »
    Remises Awards Biovision 2016

    The Investor Conference of Biovision is a unique opportunity for…

    Read more »
    QDM220615

    “Destroying complex shape tumors using MR guided ultrasound probes, opening the Blood-Brain Barrier with…

    Read more »
    HirshCarpentier

    Annual day of the Technology Transfert Department of APHP (Assistance…

    Read more »